The united states pharmaceutical 3PL market size is estimated at USD 21.58 billion in 2026, and is expected to reach USD 28.70 billion by 2031, at a CAGR of 5.87% during the forecast period (2026-2031). This report is Segmented by Service Type (Domestic Transportation Management, and More), Temperature Type (Cold Chain and Non-Cold Chain), End User (Pharmaceutical Manufacturers, and More), Product Type (Prescription Drugs, OTC and Consumer Health Products, Biopharmaceuticals and Biosimilars, Cell and Gene Therapies, and More). The Market Forecasts are Provided in Terms of Value (USD).
Second-level value migration appears in control-tower contracts that bundle transport planning with SKU-level visibility, predictive ETA, and exception management. Providers that combine network modeling, IoT sensors, and AI routing engines can trim spoilage claims by double digits and command service premiums despite rate pressure elsewhere. The asset-light brokerage community, typified by RXO, leverages digital freight platforms to place compliant carriers into time-critical lanes at scale, demonstrating that technology parity matters as much as warehouse footprint. Competitive differentiation within the United States pharmaceutical 3PL market therefore hinges on integrated data, continuous quality assurance, and adherence to GDP metrics rather than raw trailer counts alone.
Non-cold-chain activities still delivered 63.5% of 2025 revenue, yet cold-chain services will compound at 9.8% CAGR (2026-2031) as therapeutic pipelines tilt toward biologics, GLP-1 injectables, and mRNA vaccines. The United States pharmaceutical 3PL market size attributable to refrigerated and cryogenic handling will cross USD 12 billion by 2031. Residential demand for insulin, weight-management drugs, and specialty oncology infusions is pushing 3PLs to adopt passive-cool parcel systems with vacuum-insulated panels that keep temperatures stable for 72 hours without dry ice. Cryogenic shipments below -70 °C form a fast-growing niche because CAR-T therapies and certain viral-vector payloads require liquid nitrogen back-up systems.
Carriers that retrofit warehouses with -80 °C chambers and vapor shippers establish a protective moat because such infrastructure is expensive and subject to strict safety codes. However, a parallel effort is underway among drug makers to engineer room-temperature stable biologics that could soften cold-chain growth beyond 2030, tempering long-term expectations for the United States pharmaceutical 3PL market.
United States Pharmaceutical 3PL Market Trends and Insights
Rise of Specialty Biologics Requiring Strict Cold-Chain Compliance
Specialty biologics already represent more than half of new drug approvals, and most degrade within minutes of temperature excursion, so 3PLs now deploy sensors that record data every 15 seconds and feed alerts into control towers for immediate corrective action. Facilities in Louisville and Dallas operated by UPS Healthcare keep redundant chillers and generators on standby, ensuring 2 °C to 8 °C integrity even during grid outages. Autologous cell therapies add a time constraint because patient-derived cells must reach infusion sites within 48 hours. These dynamics shorten allowable transit windows, spur demand for dedicated couriers, and elevate the strategic importance of the United States pharmaceutical 3PL market for hospital oncology centers. Providers that document temperature history in immutable ledgers using blockchain gain an audit advantage when FDA inspectors review chain-of-custody records. As biologic launch pipelines remain robust, cold-chain growth outpaces ambient services, sustaining above-market pricing power for compliant operators across the United States pharmaceutical 3PL market.E-Pharmacy Parcelization Boosting Last-Mile Temperature-Control Needs
Relaxed post-pandemic regulations triggered double-digit prescription mail-order growth, and Amazon Pharmacy’s 2024 move into cooled residential delivery further expanded demand. Average parcel weight fell from 3.2 kg in 2020 to 1.8 kg in 2025, pushing per-unit logistics costs higher even as volumes surged. FedEx Healthcare’s SenseAware ID devices now travel inside every specialty-drug parcel, broadcasting GPS and temperature telemetry in real time. Routing algorithms recombine hundreds of small orders into densely scheduled micro-routes that meet two-hour delivery promises, a capability that large 3PLs leverage to win exclusive mail-order contracts. The trend positions e-pharmacy traffic as a structural growth engine for the United States pharmaceutical 3PL market through the forecast horizon. Nevertheless, soaring residential mileage raises sustainability concerns, prompting carriers to experiment with electric vans and reusable insulated packs to satisfy shippers’ ESG targets.Intense Cost Pressure from Pharma Tendering Models
Pharmaceutical producers increasingly award multiyear logistics contracts through reverse auctions that demand annual unit-cost cuts even when diesel and labor expenses climb. Generic-drug distribution margins slipped below 3% in 2025, down more than 100 basis points in five years, and biosimilar shippers benchmark rates against cheaper small-molecule corridors, limiting cold-chain cost recovery. Fixed-price clauses stifle innovation because 3PLs hesitate to propose serialization upgrades without cost-pass-through certainty. Some sponsors trial gain-sharing schemes, yet procurement teams still prioritize budget certainty. For cash-constrained carriers, tighter pricing reduces available funds for DSCSA or refrigerant compliance, risking future contract eligibility. This pressure slows capital refresh cycles, restraining the potential CAGR for the United States pharmaceutical 3PL market despite healthy volume growth.Other drivers and restraints analyzed in the detailed report include:
- Stringent GDP and DSCSA Regulations Driving Real-Time Monitoring Investments
- United States Refrigerant Phase-Down Forcing Rapid Cold-Warehouse Retrofit
- GDP-Trained Labor Shortage Across Warehousing and Trucking
Segment Analysis
In 2025, domestic transportation management contributed 42.2% of total revenue, but value-added warehousing and distribution is on track for an 8.1% CAGR between 2026-2031 as DSCSA mandates push serialization, aggregation, and kitting tasks closer to inventory nodes. Facility operators installing automated case-packing arms tie barcode aggregation into warehouse-execution systems, allowing manufacturers to outsource compliance overhead without increasing their fixed assets. Domestic trucking remains essential for door-to-door reach, yet mileage-based rates face payer pushback, nudging carriers toward drop-trailer programs and dedicated contract carriage that allow higher asset turns. International airfreight, though smaller in volume, carries a premium yield per kilo because of customs-clearance complexity and cryogenic handling needs, reinforcing multimodal diversification strategies across the United States pharmaceutical 3PL market.Second-level value migration appears in control-tower contracts that bundle transport planning with SKU-level visibility, predictive ETA, and exception management. Providers that combine network modeling, IoT sensors, and AI routing engines can trim spoilage claims by double digits and command service premiums despite rate pressure elsewhere. The asset-light brokerage community, typified by RXO, leverages digital freight platforms to place compliant carriers into time-critical lanes at scale, demonstrating that technology parity matters as much as warehouse footprint. Competitive differentiation within the United States pharmaceutical 3PL market therefore hinges on integrated data, continuous quality assurance, and adherence to GDP metrics rather than raw trailer counts alone.
Non-cold-chain activities still delivered 63.5% of 2025 revenue, yet cold-chain services will compound at 9.8% CAGR (2026-2031) as therapeutic pipelines tilt toward biologics, GLP-1 injectables, and mRNA vaccines. The United States pharmaceutical 3PL market size attributable to refrigerated and cryogenic handling will cross USD 12 billion by 2031. Residential demand for insulin, weight-management drugs, and specialty oncology infusions is pushing 3PLs to adopt passive-cool parcel systems with vacuum-insulated panels that keep temperatures stable for 72 hours without dry ice. Cryogenic shipments below -70 °C form a fast-growing niche because CAR-T therapies and certain viral-vector payloads require liquid nitrogen back-up systems.
Carriers that retrofit warehouses with -80 °C chambers and vapor shippers establish a protective moat because such infrastructure is expensive and subject to strict safety codes. However, a parallel effort is underway among drug makers to engineer room-temperature stable biologics that could soften cold-chain growth beyond 2030, tempering long-term expectations for the United States pharmaceutical 3PL market.
Complete Report Scope:
- By Service Type
- Domestic Transportation Management (DTM)
- Roadways
- Railways
- Airways
- Waterways
- International Transportation Management (ITM)
- Roadways
- Railways
- Airways
- Waterways
- Value-Added Warehousing and Distribution (VAWD)
- Domestic Transportation Management (DTM)
- By Temperature Type
- Cold Chain
- Non-cold Chain
- By End User
- Pharmaceutical Manufacturers
- Biotech and Biosimilar Manufacturers
- Clinical Research and Trial Sponsors
- Hospitals and Retail Pharmacies
- Healthcare Distributors and Wholesalers
- E-pharmacies and Direct-to-Patient Services
- By Product Type
- Prescription Drugs
- OTC and Consumer Health Products
- Biopharmaceuticals and Biosimilars (ex-CGT)
- Cell and Gene Therapies
- Vaccines and Blood-derived Products
- Veterinary Pharmaceuticals and Animal Health Products
- Medical Devices, Diagnostics and Combination Products
- Clinical-trial Materials (Investigational Medicinal Products)
- Others
- By Geography
- Northeast
- Midwest
- Southeast
- Southwest
- West
List of Companies Covered in this Report:
- Almac Group Clinical Services
- Biocair
- Catalent Clinical Supply Services
- CMA CGM Group (Including CEVA Logistics)
- DHL Group
- DSV A/S
- FedEx
- GEODIS
- JAS Worldwide Pharma and Healthcare
- Kerry Logistics Network
- Kuehne+Nagel
- Nippon Express Co., Ltd.
- SF Express (Health)
- United Parcel Service of America, Inc. (UPS)
- World Courier (Cencora)
- XPO Logistics
- Yusen Logistics
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
Table of Contents
1 Introduction
4 Market Landscape
5 Market Size and Growth Forecasts (Value)
6 Competitive Landscape
7 Market Opportunities and Future Outlook
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Almac Group Clinical Services
- Biocair
- Catalent Clinical Supply Services
- CMA CGM Group (Including CEVA Logistics)
- DHL Group
- DSV A/S
- FedEx
- GEODIS
- JAS Worldwide Pharma and Healthcare
- Kerry Logistics Network
- Kuehne+Nagel
- Nippon Express Co., Ltd.
- SF Express (Health)
- United Parcel Service of America, Inc. (UPS)
- World Courier (Cencora)
- XPO Logistics
- Yusen Logistics
